噻托溴铵联合舒利迭治疗慢性阻塞性肺疾病稳定期患者的临床疗效

Clinical effect of tiotropium combined with Seretide in the treatment of patients with chronic obstructive pulmonary diseases

目的分析噻托溴铵联合舒利迭治疗慢性阻塞性肺疾病稳定期患者的临床疗效。方法选取天津市第四中心医院2015年6月～2017年5月收治的80例慢性阻塞性肺疾病稳定期患者为研究对象，随机分为2组，每组各40例。对照组采用噻托溴铵治疗，实验组进行噻托溴铵联合舒利迭治疗。比较实验组与对照组治疗前后的动脉二氧化碳分压、氧分压及FEV1和FEV1/FVC。结果治疗后，实验组FEV1为（2.27±0.45）L显著高于对照组的（1.80±0.20）L（P＜0.05）。实验组FEV1/FVC为（68.90±5.22），对照组FEV1/FVC为（54.33±4.20），2组比较差异具有统计学意义（P＜0.05）。实验组经过治疗后，氧分压为（75.09±6.33）mmHg显著高于对照组氧分压（66.33±4.76）mmHg（P＜0.05），动脉二氧化碳（44.30±2.67）mmHg显著低于对照组（P＜0.05）。结论噻托溴铵联合舒利迭治疗慢性阻塞性肺疾病稳定期患者的临床疗效较为理想，可显著改善患者肺功能，缓解临床症状。

Objective To study the clinical efficacy of tiotropium combined with Seretide in the treatment of patients with chronic obstructive pulmonary diseases.Methods80cases of patients with stable chronic obstructive pulmonary disease patients treated in our hospital from June2015to May2017as the research object,they were randomly divided into two groups,with40cases in each group.The control group was treated with tiotropium bromide,the experimental group was treated with tiotropium combined with Seretide.The arterial carbon dioxide partial pressure,oxygen partial pressure,FEV1and FEV1,/FVC were compared between the experimental group and the control group before and after treatment.Results After the corresponding treatment,FEV1in the experimental group was(2.27±0.45)L,significantly higher than that of the control group(1.80±0.20)L(P<0.05).The FEV1/FVC in the experimental group was(68.90±5.22),in the control group was(54.33±4.20),the difference between the two groups was statistically significant(P<0.05).After treatment,the oxygen partial pressure in the experimental group was(75.09±6.33)mmHg,which was significantly higher than that in the control group(66.33±4.76)mmHg(P<0.05).The arterial carbon dioxide in the experimental group was(44.30±2.67)mmHg,which was significantly lower than that in the control group(P<0.05).Conclusion The clinical effect of tiotropium combined with Seretide in the treatment of patients with chronic obstructive pulmonary disease is ideal,can significantly improve the pulmonary function of patients,relieve the clinical symptoms.